Harmony Biosciences Holdings, Inc. Common Stock (HRMY) Stock
Key stats
- Market cap
- $2.01B
- Price / Earnings ratio
- 11.0x
- EPS (TTM)
- $3.09
- Volume
- Loading
- 52-week high
- $43.49
- 52-week low
- $25.90
Source: third-party data provider, as of November 13, 2026
Compare with HRMY
Recent news

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
HRMY

Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors
Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors
HRMY

HRMY or ARGX: Which Is the Better Value Stock Right Now?
HRMY or ARGX: Which Is the Better Value Stock Right Now?
HRMY

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
HRMY
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 38.04
- MACD 12/26/9
- -1.42
- EMA 9 of MACD
- -1.11
- MACD histogram
- -0.31
- SMA 50
- $38.99
- Price below SMA 50
- EMA 50
- $37.54
- Price below EMA 50
- SMA 200
- $34.60
- Price below SMA 200
- EMA 200
- $35.91
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
HRMY

Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors
Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors
HRMY

HRMY or ARGX: Which Is the Better Value Stock Right Now?
HRMY or ARGX: Which Is the Better Value Stock Right Now?
HRMY

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
HRMY

HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
HRMY

Why Harmony Biosciences Stock Got Mashed on Monday
Why Harmony Biosciences Stock Got Mashed on Monday
HRMY

Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit
Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit
HRMY

HRMY vs. CSLLY: Which Stock Is the Better Value Option?
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
HRMY

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
HRMY

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
HRMY
News tone: automated (AI) classification of the article's content, not a price prediction.
About Harmony Biosciences Holdings, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey M. Dayno M.D. | President, CEO & Director | 1957 |
| Mr. Jeffrey S. Aronin | Founder & Non-Executive Chairman | 1968 |
| Mr. Peter Anastasiou | Chief Operating Officer | 1970 |
| Dr. Kumar Budur M.D., M.S. | Executive VP and Chief Medical & Scientific Officer | 1971 |
| Mr. Andrew Serafin J.D., M.B.A. | Executive VP & Chief Strategy Officer | 1975 |
| Mr. Adam Zaeske | Executive VP & Chief Commercial Officer | 1973 |
| Mr. Stephen Mollichella | Senior VP, Controller & Interim Principal Financial Officer | — |
| Brennan Doyle | VP & Head of Investor Relations | — |
| Mr. Christian Ulrich J.D. | Executive VP, General Counsel & Corporate Secretary | — |
| Ms. Tricia Glover | Chief Compliance Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 38.04
- MACD 12/26/9
- -1.42
- EMA 9 of MACD
- -1.11
- MACD histogram
- -0.31
- SMA 50
- $38.99
- Price below SMA 50
- EMA 50
- $37.54
- Price below EMA 50
- SMA 200
- $34.60
- Price below SMA 200
- EMA 200
- $35.91
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $50.00
- Average
- $55.00
- High
- $60.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -16.9 | +19.9 | ||||||||||
| 2022 | -19.9 | +6.4 | +21.4 | -9.9 | -3.3 | +14.0 | -2.4 | -10.8 | -2.4 | +14.5 | +0.9 | -8.2 |
| 2023 | -9.0 | -8.7 | -23.7 | -2.9 | +5.6 | +2.3 | +1.5 | +6.6 | -9.2 | -27.4 | +18.5 | +6.0 |
| 2024 | +2.4 | +2.6 | +4.6 | -6.4 | -2.9 | +0.6 | +11.3 | +10.0 | +10.0 | -18.1 | +4.8 | -2.0 |
| 2025 | +11.3 | -12.5 | +3.1 | -9.1 | +15.5 | -11.1 | +9.8 | +7.2 | -25.7 | +6.1 | +20.3 | +5.4 |
| 2026 | -2.3 | -24.6 | -3.1 | +11.8 | -0.8 | +14.5 | -2.1 | +10.6 | -4.8 | -2.0 | -9.7 |



